Funding
← Back to your selection

TCGX

Activity from announced rounds

Activity in this selectionUnited States · Oct 23, 2026 · Jan 1, 2026
Rounds participated in
3
Confirmed lead rounds
—
3 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$755M
3 disclosed · full round size, not this investor’s share

By stage

Series B2
Series A1

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
Mirador Therapeutics

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases

$250MSeries B
Role not disclosed